19,300 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Avidity Partners Management LP

Avidity Partners Management LP purchased a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,300 shares of the company’s stock, valued at approximately $2,020,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of PVLA. Group One Trading LLC grew its holdings in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics in the third quarter worth about $36,000. JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Palvella Therapeutics in the second quarter worth about $85,000. Finally, BNP Paribas Financial Markets purchased a new stake in Palvella Therapeutics in the second quarter worth about $104,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 20.50% of the stock is currently owned by insiders.

Palvella Therapeutics Stock Up 2.3%

NASDAQ:PVLA opened at $108.81 on Friday. The company’s 50 day moving average price is $119.52 and its 200-day moving average price is $108.46. Palvella Therapeutics, Inc. has a 52 week low of $20.20 and a 52 week high of $151.18. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -26.09 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PVLA. Stifel Nicolaus set a $250.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, February 24th. BTIG Research upped their price objective on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Chardan Capital restated a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Mizuho upped their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.